Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoru Sagae

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
International Journal of Clinical Oncology|August 19, 2007
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysisMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2009
The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective studyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 2, 2010
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma StudyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
Oncology Reports|November 8, 2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryMasashi Takano, Yoshihiro Kikuchi, Nobuo Yaegashi, et al.
Journal of the National Cancer Institute|March 18, 2004
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)Gordon J S Rustin, Michael Quinn, Tate Thigpen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Anticancer Research|April 1, 2009
Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancerDaisuke Aoki, Yoh Watanabe, Toshiko Jobo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinomaSatoru Sagae, Nobuyuki Susumu, Akila N Viswanathan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the FutureSatoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
International Journal of Clinical Oncology|November 12, 2010
Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 editionSatoru Nagase, Hidetaka Katabuchi, Masamichi Hiura, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
International Journal of Clinical Oncology|August 19, 2007
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysisMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2009
The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective studyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 2, 2010
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma StudyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
Oncology Reports|November 8, 2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryMasashi Takano, Yoshihiro Kikuchi, Nobuo Yaegashi, et al.
Journal of the National Cancer Institute|March 18, 2004
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)Gordon J S Rustin, Michael Quinn, Tate Thigpen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Anticancer Research|April 1, 2009
Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancerDaisuke Aoki, Yoh Watanabe, Toshiko Jobo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinomaSatoru Sagae, Nobuyuki Susumu, Akila N Viswanathan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the FutureSatoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
International Journal of Clinical Oncology|November 12, 2010
Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 editionSatoru Nagase, Hidetaka Katabuchi, Masamichi Hiura, et al.
Pageof 5